D. Forer

发表

Phase I Drug and Light Dose-Escalation Trial of Motexafin Lutetium and Far Red Light Activation (Phototherapy) in Subjects With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention and Stent Deployment: Procedural and Long-Term Results

A. Yeung, P. Fitzgerald, C. Rogers, 2003, Circulation.

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.

A. Armstrong, C. Higano, B. Tombal, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration‐resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial

J. Carles, T. Dorff, C. Higano, 2017, Clinical genitourinary cancer.

Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.

F. Saad, A. Armstrong, C. Sternberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.

H. Scher, J. Bono, Y. Loriot, 2013 .

Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.

H. Scher, P. Mulders, K. Fizazi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

H. Scher, C. Higano, M. Taplin, 2015, European urology.

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.

E. Basch, H. Scher, D. Cella, 2014, The Lancet. Oncology.

Enzalutamide in castration‐resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial

H. Scher, J. Bono, Y. Loriot, 2017, Cancer.

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.

H. Scher, J. Bono, C. Sternberg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

767PRESPONSE RATES AND OUTCOMES WITH ENZALUTAMIDE FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER AND VISCERAL DISEASE IN THE PREVAIL TRIAL.

J. Carles, C. Higano, B. Tombal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel

F. Saad, H. Scher, A. Armstrong, 2017, Cancer.

Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study.

M. Morris, H. Scher, D. Rathkopf, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research

D. Penson, S. Flanders, D. Lin, 2016, Future oncology.